[Unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for myelodysplastic syndrome with anti-HLA antibodies].

Authors

Masanori Sakata, Masuho Saburi, Katsuya Kawano, Hiroyuki Takata, Yasuhiko Miyazaki, Eiichi Ohtsuka

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 67. Issue 7. Pages 703-708.

Abstract

A 65-year-old woman was diagnosed with myelodysplastic syndrome following the detection of pancytopenia, and allogeneic hematopoietic stem cell transplantation was planned. No HLA-matched related or unrelated donor was available. Anti-HLA antibody screening showed broad, high mean fluorescence intensity (MFI) antibodies against HLA-A, -B, -C, and -DR. The maximum MFI was 21,919, and high-MFI donor-specific antibodies (DSA) against HLA-haploidentical related donors were detected. Because reduced-intensity conditioning and graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide were planned, donor selection prioritized avoidance of DSA over HLA compatibility. Consequently, peripheral blood stem cell transplantation was performed from an unrelated donor with two HLA mismatches. Engraftment was achieved promptly, and neither acute nor chronic GVHD developed. The patient remains in complete remission at nine months after transplantation.

PMID:
42543637
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.